Opinion|Videos|December 20, 2024
Dosing Frequency, and Adverse Event Management With Bispecific Therapy
Panelists discuss how an early adverse event for this drug class no matter what the mechanism or target is, is cytokine release syndrome (CRS), and it tends to occur on a timescale that is predictable. When treating patients in the outpatient setting, they receive dexamethasone, given at the first fever, which is the first sign of cytokine release syndrome (CRS) and helps mitigate it.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you describe the CRS and ICANS that we see with the bispecifics, both BCMA and GPRC5D, and how we are approaching treating these patients in the inpatient and outpatient setting?
Advertisement
Related to this article
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.
Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
In 60 patients undergoing gastrectomy, pre-consultation video aids shortened in-person consent visits and no patient had high decisional conflict.
Advertisement
Advertisement
Trending on CancerNetwork
1
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
2
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
3
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5